ATE333879T1 - Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum - Google Patents

Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum

Info

Publication number
ATE333879T1
ATE333879T1 AT97944028T AT97944028T ATE333879T1 AT E333879 T1 ATE333879 T1 AT E333879T1 AT 97944028 T AT97944028 T AT 97944028T AT 97944028 T AT97944028 T AT 97944028T AT E333879 T1 ATE333879 T1 AT E333879T1
Authority
AT
Austria
Prior art keywords
antidepressant
receptor antagonists
anxiolytic
cns
penetrating
Prior art date
Application number
AT97944028T
Other languages
English (en)
Inventor
Emma Joanne Carlson
Nadia Melanie Rupniak
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9620880.6A external-priority patent/GB9620880D0/en
Priority claimed from GBGB9716458.6A external-priority patent/GB9716458D0/en
Priority claimed from GBGB9716460.2A external-priority patent/GB9716460D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE333879T1 publication Critical patent/ATE333879T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
AT97944028T 1996-10-07 1997-10-07 Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum ATE333879T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9620880.6A GB9620880D0 (en) 1996-10-07 1996-10-07 Therapeutic use
GBGB9716458.6A GB9716458D0 (en) 1997-08-04 1997-08-04 In vivo assay
GBGB9716460.2A GB9716460D0 (en) 1997-08-04 1997-08-04 In vivo assay

Publications (1)

Publication Number Publication Date
ATE333879T1 true ATE333879T1 (de) 2006-08-15

Family

ID=27268509

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97944028T ATE333879T1 (de) 1996-10-07 1997-10-07 Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum

Country Status (8)

Country Link
EP (1) EP0929303B1 (de)
JP (1) JP2001502311A (de)
AT (1) ATE333879T1 (de)
AU (1) AU726745B2 (de)
CA (1) CA2266773A1 (de)
DE (1) DE69736390T2 (de)
ES (1) ES2267153T3 (de)
WO (1) WO1998015277A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
CA2298777A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating mania
GB9812617D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
CA2334611A1 (en) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist for treating psychiatric disorders
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
CA2324813A1 (en) * 1999-11-10 2001-05-10 Susan Beth Sobolov-Jaynes Combination treatment for depression and anxiety
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (de) * 2000-09-28 2003-03-26 Pfizer Products Inc. Ein NK-3 rezeptorantagonisten und ein ZNS-penetrierende NK-1 rezeptorantagonisten enthaltende Zusammensetzung zur Behandlung von Depression und Angst
SK252004A3 (sk) * 2001-07-20 2005-03-04 Pfizer Products Inc. Použitie antagonistov receptora NK-1 na výrobu liečiva na liečenie abnormálneho úzkostného správania domácich zvierat a spôsob screeningu skúšanej zlúčeniny s cieľom stanoviť anxiolytickú účinnosť u psov
US20040006135A1 (en) * 2002-06-19 2004-01-08 Pfizer Inc. Combination treatment for depression and anxiety
DK1631557T3 (da) * 2003-06-12 2007-05-07 Btg Int Ltd Cyklisk hydroxylamin som psykoaktive forbindelser
BRPI0415010B8 (pt) * 2003-10-24 2021-05-25 Lilly Co Eli formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
WO2014099503A1 (en) 2012-12-20 2014-06-26 Inception 2, Inc. Triazolone compounds and uses thereof
PE20160880A1 (es) 2013-09-06 2016-09-22 Inception 2 Inc Compuestos de triazolona y usos de los mismos
EA202090180A1 (ru) * 2017-06-30 2020-05-26 Чейс Терапьютикс Корпорейшн Композиции nk1-антагониста и способы лечения депрессии

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
MX9703988A (es) * 1994-12-12 1998-02-28 Omeros Med Sys Inc SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO.
PE38997A1 (es) * 1994-12-13 1997-10-02 Novartis Ag Antagonista de taquicinina
WO1996024353A1 (en) * 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders

Also Published As

Publication number Publication date
WO1998015277A3 (en) 1998-05-22
AU4567397A (en) 1998-05-05
CA2266773A1 (en) 1998-04-16
DE69736390T2 (de) 2007-07-26
EP0929303B1 (de) 2006-07-26
JP2001502311A (ja) 2001-02-20
ES2267153T3 (es) 2007-03-01
AU726745B2 (en) 2000-11-16
WO1998015277A2 (en) 1998-04-16
EP0929303A2 (de) 1999-07-21
DE69736390D1 (de) 2006-09-07

Similar Documents

Publication Publication Date Title
ATE333879T1 (de) Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
DE69616480T2 (de) Piperidinderivate als neurokininantagonisten
ATE200279T1 (de) Herstellung von 3,4,4-trisubstituiertem piperidinyl-n-alkylcarboxylaten und zwischenverbindungen, verwendbar als opioid antagonisten
ATE209207T1 (de) Androgen rezeptor modulator verbindungen und verfahren
DE69323768T2 (de) Pyrrolopyrimidine als crf antagonisten
TR199700644T1 (xx) Serotonin-ili�kili sistemler �zerinde etkiye sahip bile�ikler.
DE69721008T2 (de) Bicyclische pyrimidine derivate und ihre verwendung als antikoagulantien
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
HK1029595A1 (en) Cyclic antagonists of c5a receptors and g protein-coupled receptors
DE69331190D1 (de) Überbrückte azabicyclische derivate als substanz p antagonisten
DE69412067D1 (de) Substituierte spiro-azaringen als tachykinine rezeptor antagonisten
NO986110L (no) IL-8 reseptor-antagonister
UA27776C2 (uk) Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
ATE390917T1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
DE69938786D1 (de) Die verwendung von peptiden von il-2 und peptid-derivaten als therapeutische wirkstoffe
ATE259230T1 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
DK0639275T3 (da) Hidtil ukendte GABAa-receptorundertyper og fremgangsmåder til screening af lægemiddelforbindelser under anvendelse af imidazoquinoxaliner og pyrrolopyimidiner til binding til GABAa-receptorundertyper
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
BR9803385A (pt) AtropisÈmeros de 2,3-dissubstituìdo-(5,6)-heteroaril condensado-pirimidin-4-onas.
DE69419157D1 (de) Tetrahydro-1h-benzazepinone und hexahydro azepinone als selektive cholecystokinin-b rezeptor antagonisten
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE182467T1 (de) Verwendung von antagonisten oder partiellen agonisten am 5-ht 1a-rezeptor zur behandlung und prävention von kognitiven störungen
DE69617700D1 (de) Neue kondensierten isochinoline als dopamin-rezeptor-liganden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties